News | 24 February 2022
Novavax ships first consignment of Covid-19 vaccine to European countries
The first wave of shipments includes several countries, such as Germany, France and Austria
The first wave of shipments includes several countries, such as Germany, France and Austria
This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Collaboration in the industry needs to be institutionalised to drive the growth.
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
The sale is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
